Yakult initiates phase I trial in multiple myeloma with perifosine in Japan

Friday, June 29, 2012 12:12 PM

Aeterna Zentaris’ Japanese partner Yakult Honsha has initiated a phase I trial in multiple myeloma with perifosine, the company's oral Akt/PI3K inhibitor drug.

Yakult, who is sponsoring and conducting the trial in Japan, reported that the first patient has been dosed with perifosine.

The open-label, two step phase I trial in which perifosine is combined with bortezomib (Velcade) and dexamethasone in patients with refractory multiple myeloma who have previously been treated with bortezomib. The trial is expected to include a total of 18 patients (6 in step one and 12 in step two). Patients will receive perifosine daily (50mg, Days 1-21) in combination with  bortezomib (1.3 mg/m, Days 1, 4, 8 and 11) and dexamethasone (20mg, Days 1, 2, 4, 5, 8, 9,

 11 and 12) according to a three-week cycle (21 days ± 3 days). The primary endpoint is safety while secondary endpoints include response rate, progression-free survival, and time to tumor progression.

"We would like to thank our partner Yakult for their close collaboration in initiating this important phase I trial in multiple myeloma which is necessary at this time in order to comply with Japan's specific registration requirements,” said Juergen Engel, PhD, president and CEO of Aeterna Zentaris. “Perifosine [is] also currently in a phase III trial in other parts of the world in multiple myeloma—for which we expect to reach an interim analysis in the first quarter of next year."

Share:          
CWWeekly

March 30

Icon, Carnegie Mellon partner to research ways to improve study patients' understanding of Informed Consent

Veeva launches OpenKey, partner program to unlock difficult access to, restrictions on customer reference data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs